MHY908

MHY908 is a potent dual agonist of PPARα and PPARγ[1]. MHY908 also inhibits melanogenesis through inhibition of mushroom tyrosinase activity[2].

Product Specifications

CAS Number

[1393371-39-5]

UNSPSC

12352005

Hazard Statement

H302-H315-H319-H335

Target

PPAR

Type

Reference compound

Related Pathways

Cell Cycle/DNA Damage; Metabolic Enzyme/Protease; Vitamin D Related/Nuclear Receptor

Applications

Metabolism-protein/nucleotide metabolism

Field of Research

Cancer; Metabolic Disease

Assay Protocol

https://www.medchemexpress.com/mhy908.html

Solubility

10 mM in DMSO

Smiles

CC(OC1=CC=C(C=C1)C2=NC3=CC(Cl)=CC=C3S2)(C(O)=O)C

Molecular Formula

C17H14ClNO3S

Molecular Weight

347.82

Precautions

P261-P264-P270-P271-P280-P302+P352-P304+P340-P305+P351+P338-P330-P362+P364-P403+P233-P405-P501

References & Citations

[1]Park MH, et al. Potent anti-diabetic effects of MHY908, a newly synthesized PPAR α/γ dual agonist in db/db mice. PLoS One. 2013 Nov 14;8 (11) :e78815. |[2]Park MH, et al. Inhibition of melanogenesis by 2-[4- (5-chlorobenzo[d]thiazol-2-yl) phenoxy]-2-methylpropanoic acid (MHY908) . Arch Pharm Res. 2015 Apr;38 (4) :505-11.